Anagrelide treatment in myeloproliferative disorders

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 3, 2006, Pages 260-266

  Birgegard, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anagrelide; Essential thrombocythemia; Myeloproliferative disease; Platelet reduction; Thrombocytosis

Indexed keywords

ANAGRELIDE; CYTOSTATIC AGENT; GAMMA INTERFERON; HYDROXYUREA; THROMBOREDUCTIN;

CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CYTOSTASIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; MYELOPROLIFERATIVE DISORDER; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT;

BLOOD PLATELETS; HUMANS; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES;

EID: 33646494509     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939437     Document Type: Review

References (31)

1. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-392
2. Sastre JL, Bravo A, Tembras S, Gomez R, Ulibarrena C. Leg ulcers associated with hydroxyurea therapy. Haematologica 2003;88:EIM01
3. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996;22(suppl 1):135-142
4. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 2005;90:1333-1338
5. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon a-2b therapy in polycythemia vera and essential thrombocythemia. Feasibility, clinical and biological effects and impact on quality of life. Cancer 2006. In press
6. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999;33:207-218
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
8. Gillespie E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem Pharmacol 1988;37:2866-2868
9. Hong Y, Erusalimsky JD. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets 2002;13:381-386
10. Thiele J, Ollig S, Schmitt-Graff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 2005;20:1071-1076
11. Hong Y, Wang G, Gutierrez del Arroyo A, Hernandez J, Skene C, Erusalimsky J. Comparison between anagrelide and hydroxycarbamide in their activites against haematopoietic progenitor cell growth and differentiation: Selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006; In press
12. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;52:325-328
13. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92:69-76
14. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-54
15. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-76
16. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-43
17. Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust NZ J Med 1999;29:29-35
18. Knutsen H, Hysing J. Anagrelide in primary thrombocythemia [In Norwegian]. Tidsskr For Laegeforen 2001;121:1478-1482
19. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-1294
20. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992;77:315-317
21. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866
22. Birgegard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004;89:520-527
23. Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101:2239-2246
24. Penninga E, Jensen BA, Hansen PB, et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004;26:335-340
25. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29:481-491
26. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 1998;24:9-13
27. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-161
28. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
29. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997;23:379-383
30. James CW. Anagrelide-induced cardiomyopathy. Pharmacotherapy 2000;20:1224-1227
31. Harrison CN. Management of essential thrombocythemia Implications of the Medical Research Council Primary Thrombocythemia 1 Trial. Semin Thromb Hemost 2006; 32:283-288